AAAAAA
Results: 1-25/58
Authors:
GELBER EE
VITETTA ES
Citation: Ee. Gelber et Es. Vitetta, EFFECT OF IMMUNOSUPPRESSIVE AGENTS ON THE IMMUNOGENICITY AND EFFICACYOF AN IMMUNOTOXIN IN MICE, Clinical cancer research, 4(5), 1998, pp. 1297-1304
Authors:
GELBER EE
VITETTA ES
Citation: Ee. Gelber et Es. Vitetta, EFFECT OF IMMUNOSUPPRESSIVE AGENTS ON THE IMMUNOGENICITY AND EFFICACYOF AN IMMUNOTOXIN IN MICE, Clinical cancer research, 4(5), 1998, pp. 1297-1304
Authors:
VITETTA ES
Citation: Es. Vitetta, VASCULAR LEAK SYNDROME - A TROUBLESOME SIDE-EFFECT OF IMMUNOTHERAPY -REPLY, Immunopharmacology, 39(3), 1998, pp. 257-257
Authors:
CLINCHY B
VITETTA ES
Citation: B. Clinchy et Es. Vitetta, THE USE OF AN ANTI-CD3 IMMUNOTOXIN TO PREVENT THE DEVELOPMENT OF LYMPHOPROLIFERATIVE DISEASE IN SCID PBL MICE/, Journal of immunological methods, 218(1-2), 1998, pp. 141-153
Authors:
UHR JW
SCHEUERMANN RH
STREET NE
VITETTA ES
Citation: Jw. Uhr et al., CANCER DORMANCY - OPPORTUNITIES FOR NEW THERAPEUTIC APPROACHES, Nature medicine, 3(5), 1997, pp. 505-509
Authors:
KAPLAN LD
ROBLES R
KAHN JO
SCHINDLER J
GHETIE V
VITETTA ES
Citation: Ld. Kaplan et al., PHASE-1 TRIAL OF ANTI-CD22 RICIN-A-CHAIN IMMUNOTOXIN (IGG-RFB4-DGA) FOR TREATMENT OF AIDS-LYMPHOMA, Journal of acquired immune deficiency syndromes and human retrovirology, 14(4), 1997, pp. 90-90
Authors:
GHETIE MA
GHETIE V
VITETTA ES
Citation: Ma. Ghetie et al., IMMUNOTOXINS FOR THE TREATMENT OF B-CELL LYMPHOMAS, Molecular medicine, 3(7), 1997, pp. 420-427
Authors:
EPZSTEYN S
VITETTA ES
YEFENOF E
Citation: S. Epzsteyn et al., PROPHYLACTIC INTERVENTION IN RADLV-INDUCED LYMPHOMAGENESIS WITH AN ANTI-IL-4 MONOCLONAL-ANTIBODY, Journal of immunotherapy with emphasis on tumor immunology, 20(4), 1997, pp. 287-291
Authors:
HUANG YW
BALUNA R
VITETTA ES
Citation: Yw. Huang et al., ADHESION MOLECULES AS TARGETS FOR CANCER-THERAPY, Histology and histopathology, 12(2), 1997, pp. 467-477
Authors:
BALUNA R
VITETTA ES
Citation: R. Baluna et Es. Vitetta, VASCULAR LEAK SYNDROME - A SIDE-EFFECT OF IMMUNOTHERAPY, Immunopharmacology, 37(2-3), 1997, pp. 117-132
Authors:
CHOU CS
RAMILO O
VITETTA ES
Citation: Cs. Chou et al., HIGHLY PURIFIED CD25(-) RESTING T-CELLS CANNOT BE INFECTED DE-NOVO WITH HIV-1, Proceedings of the National Academy of Sciences of the United Statesof America, 94(4), 1997, pp. 1361-1365
Authors:
GHETIE MA
PODAR EM
ILGEN A
GORDON BE
UHR JW
VITETTA ES
Citation: Ma. Ghetie et al., HOMODIMERIZATION OF TUMOR-REACTIVE MONOCLONAL-ANTIBODIES MARKEDLY INCREASES THEIR ABILITY TO INDUCE GROWTH ARREST OR APOPTOSIS OF TUMOR-CELLS, Proceedings of the National Academy of Sciences of the United Statesof America, 94(14), 1997, pp. 7509-7514
Authors:
ARMSTRONG JM
VITETTA ES
Citation: Jm. Armstrong et Es. Vitetta, THE ROLES OF FAS AND PERFORIN IN LAK T-CELL BISPECIFIC ANTIBODY-MEDIATED KILLING OF THE MURINE B-LYMPHOMA CELLS, BCL(1) (VOL 68, PG 822, 1996)/, International journal of cancer, 70(6), 1997, pp. 728-728
Authors:
VITETTA ES
TUCKER TF
RACILA E
HUANG YW
MARCHES R
LANE N
SCHEUERMANN RH
STREET NE
WATANABE T
UHR JW
Citation: Es. Vitetta et al., TUMOR DORMANCY AND CELL SIGNALING .5. REGROWTH OF THE BCL1 TUMOR AFTER DORMANCY IS ESTABLISHED, Blood, 89(12), 1997, pp. 4425-4436
Authors:
BALUNA R
SAUSVILLE EA
STONE MJ
STETLERSTEVENSON MA
UHR JW
VITETTA ES
Citation: R. Baluna et al., DECREASES IN LEVELS OF SERUM FIBRONECTIN PREDICT THE SEVERITY OF VASCULAR LEAK SYNDROME IN PATIENTS TREATED WITH RICIN-A CHAIN-CONTAINING IMMUNOTOXINS, Clinical cancer research, 2(10), 1996, pp. 1705-1712
Authors:
RAMILO O
HICKS PJ
BORVAK J
GROSS LM
ZHONG D
SQUIRES JE
VITETTA ES
Citation: O. Ramilo et al., T-CELL ACTIVATION AND HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION AFTER INFLUENZA IMMUNIZATION OF INFECTED CHILDREN, The Pediatric infectious disease journal, 15(3), 1996, pp. 197-203
Authors:
THRUSH GR
LARK LR
CLINCHY BC
VITETTA ES
Citation: Gr. Thrush et al., IMMUNOTOXINS - AN UPDATE, Annual review of immunology, 14, 1996, pp. 49-71
Authors:
BALUNA R
GHETIE V
OPPENHEIMERMARKS N
VITETTA ES
Citation: R. Baluna et al., FIBRONECTIN INHIBITS THE CYTOTOXIC EFFECT OF RICIN-A CHAIN ON ENDOTHELIAL-CELLS, International journal of immunopharmacology, 18(6-7), 1996, pp. 355-361
Authors:
GHETIE MA
GORDON BE
PODAR EM
VITETTA ES
Citation: Ma. Ghetie et al., EFFECT OF SUBLETHAL IRRADIATION OF SCID MICE ON GROWTH OF B-CELL LYMPHOMA XENOGRAFTS AND ON EFFICACY OF CHEMOTHERAPY AND OR IMMUNOTOXIN THERAPY/, Laboratory animal science, 46(3), 1996, pp. 305-309
Authors:
BORVAK J
CHOU CS
VANDYKE G
ROSENWIRTH B
VITETTA ES
RAMILO O
Citation: J. Borvak et al., THE USE OF CYCLOSPORINE, FK506, AND SDZ NIM811 TO PREVENT CD25(-) QUIESCENT PERIPHERAL-BLOOD MONONUCLEAR-CELLS FROM PRODUCING HUMAN-IMMUNODEFICIENCY-VIRUS, The Journal of infectious diseases, 174(4), 1996, pp. 850-853
Authors:
ARMSTRONG JM
VITETTA ES
Citation: Jm. Armstrong et Es. Vitetta, THE ROLES OF EAS AND PERFORIN IN LAK T-CELL BISPECIFIC ANTIBODY-MEDIATED KILLING OF THE MURINE B-LYMPHOMA CELLS, BCL(1)/, International journal of cancer, 68(6), 1996, pp. 822-827
Authors:
GHETIE MA
PODAR EM
GORDON BE
PANTAZIS P
UHR JW
VITETTA ES
Citation: Ma. Ghetie et al., COMBINATION IMMUNOTOXIN TREATMENT AND CHEMOTHERAPY IN SCID MICE WITH ADVANCED, DISSEMINATED DAUDI-LYMPHOMA, International journal of cancer, 68(1), 1996, pp. 93-96
Authors:
STONE MJ
SAUSVILLE EA
FAY JW
HEADLEE D
COLLINS RH
FIGG WD
STETLERSTEVENSON M
JAIN V
JAFFE ES
SOLOMON D
LUSH RM
SENDEROWICZ A
GHETIE V
SCHINDLER J
UHR JW
VITETTA ES
Citation: Mj. Stone et al., A PHASE-I STUDY OF BOLUS VERSUS CONTINUOUS-INFUSION OF THE ANTI-CD19 IMMUNOTOXIN, IGG-HD37-DGA, IN PATIENTS WITH B-CELL LYMPHOMA, Blood, 88(4), 1996, pp. 1188-1197
Authors:
BURROWS FJ
DERBYSHIRE EJ
TAZZARI PL
AMLOT P
GAZDAR AF
KING SW
LETARTE M
VITETTA ES
THORPE PE
Citation: Fj. Burrows et al., UP-REGULATION OF ENDOGLIN ON VASCULAR ENDOTHELIAL-CELLS IN HUMAN SOLID TUMORS - IMPLICATIONS FOR DIAGNOSIS AND THERAPY, Clinical cancer research, 1(12), 1995, pp. 1623-1634
Authors:
CONRY RM
KHAZAELI MB
SALEH MN
GHETIE V
VITETTA ES
LIU TP
LOBUGLIO AF
Citation: Rm. Conry et al., PHASE-I TRIAL OF AN ANTI-CD19 DEGLYCOSYLATED RICIN-A CHAIN IMMUNOTOXIN IN NON-HODGKINS-LYMPHOMA - EFFECT OF AN INTENSIVE SCHEDULE OF ADMINISTRATION, Journal of immunotherapy with emphasis on tumor immunology, 18(4), 1995, pp. 231-241